Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SMG1P5 (ImmuneEditome ID:595101)

1. Gene summary of enriched editing regions for SMG1P5

Gene summary

Gene information	Gene symbol	SMG1P5
	Gene ID	595101
	GeneSynonyms	-
	GeneCytomap	16p11.2
	GeneType	pseudo
	GeneDescription	SMG1P5, nonsense mediated mRNA decay associated PI3K related kinase pseudogene 5\|smg-1 homolog, phosphatidylinositol 3-kinase-related kinase pseudogene
	GeneModificationdate	20230329
	UniprotID	.
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr16:30282487-30284599:-	ENST00000529428.4	ENSG00000183604.13	SMG1P5	ncRNA_intronic	L1MB8,AluSq2,AluSz,MER58D,Tigger4b,AluSx1,Tigger4a	chr16:30282487-30284599:-.alignment

Top

2. Tumor-specific enriched editing regions for SMG1P5

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr16:30282487-30284599:-	SARC	EER	3.9967e-02	1.6397e-02	1.4809e+01
ENSG00000183604.13,SMG1P5	SARC	EAG	3.9967e-02	1.6397e-02	1.4809e+01

Top

3. Enriched editing regions and immune related genes for SMG1P5

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for SMG1P5

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for SMG1P5

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr16:30282487-30284599:-	ACC	EER	Macrophages_M0	1.7783e-02	0.3776
ENSG00000183604.13,SMG1P5	ACC	EAG	Macrophages_M0	1.7783e-02	0.3776
ENSG00000183604.13,SMG1P5	BLCA	EAG	NK_cells_resting	3.5670e-02	-0.1594
chr16:30282487-30284599:-	BRCA	EER	Macrophages_M2	3.8759e-03	-0.1347
ENSG00000183604.13,SMG1P5	BRCA	EAG	Macrophages_M2	3.9921e-03	-0.1341
ENSG00000183604.13,SMG1P5	CESC	EAG	T_cells_CD4_memory_activated	4.6240e-02	-0.1779
chr16:30282487-30284599:-	COAD	EER	T_cells_follicular_helper	2.4505e-02	-0.2134
ENSG00000183604.13,SMG1P5	COAD	EAG	T_cells_follicular_helper	1.4642e-02	-0.2301
chr16:30282487-30284599:-	DLBC	EER	T_cells_regulatory_(Tregs)	3.6960e-03	-0.5803
ENSG00000183604.13,SMG1P5	DLBC	EAG	T_cells_regulatory_(Tregs)	3.6960e-03	-0.5803
chr16:30282487-30284599:-	GBM	EER	Monocytes	3.9890e-02	0.2147
ENSG00000183604.13,SMG1P5	GBM	EAG	Monocytes	3.9890e-02	0.2147
chr16:30282487-30284599:-	HNSC	EER	B_cells_naive	4.7847e-03	-0.2613
ENSG00000183604.13,SMG1P5	HNSC	EAG	B_cells_naive	4.7847e-03	-0.2613
chr16:30282487-30284599:-	KICH	EER	T_cells_CD8	1.7722e-02	0.4043
ENSG00000183604.13,SMG1P5	KICH	EAG	T_cells_CD8	1.7722e-02	0.4043
chr16:30282487-30284599:-	KIRP	EER	Dendritic_cells_resting	2.4204e-02	0.2066
ENSG00000183604.13,SMG1P5	KIRP	EAG	Dendritic_cells_resting	2.4204e-02	0.2066
ENSG00000183604.13,SMG1P5	LIHC	EAG	NK_cells_resting	5.8944e-03	-0.3459
chr16:30282487-30284599:-	LUAD	EER	Neutrophils	2.6970e-02	-0.2037
ENSG00000183604.13,SMG1P5	LUAD	EAG	Neutrophils	2.6979e-02	-0.2036
chr16:30282487-30284599:-	LUSC	EER	Macrophages_M2	3.0342e-02	-0.1781
ENSG00000183604.13,SMG1P5	LUSC	EAG	Macrophages_M2	3.0342e-02	-0.1781
ENSG00000183604.13,SMG1P5	PAAD	EAG	B_cells_naive	2.1710e-02	0.3763
chr16:30282487-30284599:-	PRAD	EER	Mast_cells_resting	1.3286e-02	0.2245
ENSG00000183604.13,SMG1P5	PRAD	EAG	Mast_cells_resting	1.3493e-02	0.2240
chr16:30282487-30284599:-	READ	EER	B_cells_naive	3.7597e-03	0.4771
ENSG00000183604.13,SMG1P5	READ	EAG	B_cells_naive	3.7597e-03	0.4771
chr16:30282487-30284599:-	SARC	EER	Mast_cells_resting	3.3997e-02	0.2359
ENSG00000183604.13,SMG1P5	SARC	EAG	Mast_cells_resting	3.3997e-02	0.2359
chr16:30282487-30284599:-	SKCM	EER	B_cells_memory	2.2422e-02	-0.1876
ENSG00000183604.13,SMG1P5	SKCM	EAG	B_cells_memory	2.2422e-02	-0.1876
ENSG00000183604.13,SMG1P5	STAD	EAG	T_cells_CD4_memory_activated	2.2904e-02	0.1577
chr16:30282487-30284599:-	TGCT	EER	Macrophages_M2	4.6972e-02	-0.2575
ENSG00000183604.13,SMG1P5	TGCT	EAG	Macrophages_M2	4.6972e-02	-0.2575
chr16:30282487-30284599:-	THCA	EER	Dendritic_cells_resting	3.4935e-02	0.1433
ENSG00000183604.13,SMG1P5	THCA	EAG	Dendritic_cells_resting	3.4935e-02	0.1433
chr16:30282487-30284599:-	THYM	EER	Macrophages_M0	1.2287e-04	0.4490
ENSG00000183604.13,SMG1P5	THYM	EAG	Macrophages_M0	1.2287e-04	0.4490
chr16:30282487-30284599:-	UCEC	EER	T_cells_regulatory_(Tregs)	2.3877e-04	-0.3545
ENSG00000183604.13,SMG1P5	UCEC	EAG	T_cells_regulatory_(Tregs)	6.0797e-04	-0.3306
ENSG00000183604.13,SMG1P5	UCS	EAG	Eosinophils	3.0459e-02	0.3892
ENSG00000183604.13,SMG1P5	UVM	EAG	T_cells_CD4_memory_activated	2.9597e-02	-0.4866

Top

6. Enriched editing regions and immune gene sets for SMG1P5

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr16:30282487-30284599:-	ACC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.6986e-02	-0.3201
ENSG00000183604.13,SMG1P5	ACC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.6986e-02	-0.3201
ENSG00000183604.13,SMG1P5	BLCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	2.1607e-02	0.1741
chr16:30282487-30284599:-	BLCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.6846e-02	0.1820
ENSG00000183604.13,SMG1P5	BRCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.7944e-06	-0.2098
chr16:30282487-30284599:-	BRCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	5.4293e-06	-0.2107
ENSG00000183604.13,SMG1P5	CESC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	1.9010e-02	0.2087
chr16:30282487-30284599:-	COAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.5955e-03	0.2671
ENSG00000183604.13,SMG1P5	COAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	1.0745e-02	0.2402
chr16:30282487-30284599:-	DLBC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	7.3250e-03	0.5437
ENSG00000183604.13,SMG1P5	DLBC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	7.3250e-03	0.5437
ENSG00000183604.13,SMG1P5	ESCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.5600e-02	0.2100
chr16:30282487-30284599:-	ESCA	GSVA_HALLMARK_HEME_METABOLISM	EER	2.0221e-02	0.2202
ENSG00000183604.13,SMG1P5	GBM	GSVA_HALLMARK_APICAL_JUNCTION	EAG	2.4346e-03	0.3124
chr16:30282487-30284599:-	GBM	GSVA_HALLMARK_APICAL_JUNCTION	EER	2.4346e-03	0.3124
ENSG00000183604.13,SMG1P5	HNSC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	1.3727e-02	-0.2292
chr16:30282487-30284599:-	HNSC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.3727e-02	-0.2292
ENSG00000183604.13,SMG1P5	KIRC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	4.1695e-02	-0.1894
chr16:30282487-30284599:-	KIRC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	4.3827e-02	-0.1883
ENSG00000183604.13,SMG1P5	KIRP	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	1.2111e-02	0.2293
chr16:30282487-30284599:-	KIRP	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.2111e-02	0.2293
ENSG00000183604.13,SMG1P5	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	3.5656e-02	0.3251
ENSG00000183604.13,SMG1P5	LGG	GSVA_HALLMARK_PEROXISOME	EAG	3.2370e-03	-0.1813
chr16:30282487-30284599:-	LGG	GSVA_HALLMARK_PEROXISOME	EER	3.2370e-03	-0.1813
chr16:30282487-30284599:-	LUSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.4997e-03	-0.2323
ENSG00000183604.13,SMG1P5	LUSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	4.4997e-03	-0.2323
ENSG00000183604.13,SMG1P5	PAAD	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	1.4076e-02	-0.4004
ENSG00000183604.13,SMG1P5	PCPG	GSVA_HALLMARK_COAGULATION	EAG	1.0706e-02	0.2555
chr16:30282487-30284599:-	PCPG	GSVA_HALLMARK_COAGULATION	EER	1.0706e-02	0.2555
ENSG00000183604.13,SMG1P5	PRAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	1.6779e-03	0.2827
chr16:30282487-30284599:-	PRAD	GSVA_HALLMARK_ANGIOGENESIS	EER	1.6624e-03	0.2830
chr16:30282487-30284599:-	READ	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.8930e-02	0.3948
ENSG00000183604.13,SMG1P5	READ	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	1.8930e-02	0.3948
chr16:30282487-30284599:-	SARC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.3196e-02	-0.2252
ENSG00000183604.13,SMG1P5	SARC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.3196e-02	-0.2252
chr16:30282487-30284599:-	SKCM	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	5.1800e-03	-0.2287
ENSG00000183604.13,SMG1P5	SKCM	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	5.1800e-03	-0.2287
ENSG00000183604.13,SMG1P5	STAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	1.6401e-04	0.2584
chr16:30282487-30284599:-	STAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.5612e-04	0.2599
ENSG00000183604.13,SMG1P5	UCEC	GSVA_HALLMARK_HEME_METABOLISM	EAG	4.3392e-02	0.1985
ENSG00000183604.13,SMG1P5	UCS	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	6.3901e-03	-0.4791
ENSG00000183604.13,SMG1P5	UVM	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	3.9303e-02	-0.4640

Top

7. Enriched editing regions and drugs for SMG1P5

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr16:30282487-30284599:-	ACC	FTI.277	EER	1.0403e-02	0.4057
ENSG00000183604.13,SMG1P5	ACC	FTI.277	EAG	1.0403e-02	0.4057
ENSG00000183604.13,SMG1P5	BLCA	GSK.650394	EAG	2.3249e-02	0.1720
chr16:30282487-30284599:-	BLCA	GSK.650394	EER	1.2244e-02	0.1906
ENSG00000183604.13,SMG1P5	BRCA	GSK269962A	EAG	4.7780e-03	-0.1321
chr16:30282487-30284599:-	BRCA	GSK269962A	EER	6.0413e-03	-0.1287
ENSG00000183604.13,SMG1P5	CESC	BI.2536	EAG	2.5948e-02	0.1984
ENSG00000183604.13,SMG1P5	DLBC	Lenalidomide	EAG	1.5201e-02	0.4996
chr16:30282487-30284599:-	DLBC	Lenalidomide	EER	1.5201e-02	0.4996
chr16:30282487-30284599:-	ESCA	Imatinib	EER	3.4918e-02	-0.2004
ENSG00000183604.13,SMG1P5	GBM	GW.441756	EAG	2.9913e-05	0.4206
chr16:30282487-30284599:-	GBM	GW.441756	EER	2.9913e-05	0.4206
ENSG00000183604.13,SMG1P5	HNSC	CEP.701	EAG	3.4719e-03	-0.2715
chr16:30282487-30284599:-	HNSC	CEP.701	EER	3.4719e-03	-0.2715
ENSG00000183604.13,SMG1P5	KICH	Metformin	EAG	9.9992e-04	-0.5392
chr16:30282487-30284599:-	KICH	Metformin	EER	9.9992e-04	-0.5392
chr16:30282487-30284599:-	KIRC	Bryostatin.1	EER	4.5463e-05	-0.3707
ENSG00000183604.13,SMG1P5	KIRC	Bryostatin.1	EAG	4.9355e-05	-0.3675
chr16:30282487-30284599:-	KIRP	Cyclopamine	EER	5.4394e-03	0.2533
ENSG00000183604.13,SMG1P5	KIRP	Cyclopamine	EAG	5.4394e-03	0.2533
ENSG00000183604.13,SMG1P5	LAML	Imatinib	EAG	1.0638e-02	0.3902
chr16:30282487-30284599:-	LGG	BIBW2992	EER	3.2375e-02	-0.1322
ENSG00000183604.13,SMG1P5	LGG	BIBW2992	EAG	3.2375e-02	-0.1322
ENSG00000183604.13,SMG1P5	LIHC	Docetaxel	EAG	1.1517e-02	0.3189
ENSG00000183604.13,SMG1P5	LUAD	Methotrexate	EAG	1.5305e-02	-0.2228
chr16:30282487-30284599:-	LUAD	Methotrexate	EER	1.5312e-02	-0.2228
ENSG00000183604.13,SMG1P5	LUSC	Gemcitabine	EAG	1.2228e-03	0.2633
chr16:30282487-30284599:-	LUSC	Gemcitabine	EER	1.2228e-03	0.2633
chr16:30282487-30284599:-	OV	BI.D1870	EER	9.1542e-03	-0.1994
ENSG00000183604.13,SMG1P5	OV	BI.D1870	EAG	1.1148e-02	-0.1942
ENSG00000183604.13,SMG1P5	PAAD	ABT.888	EAG	8.3614e-03	-0.4329
ENSG00000183604.13,SMG1P5	PCPG	Dasatinib	EAG	2.9686e-04	-0.3579
chr16:30282487-30284599:-	PCPG	Dasatinib	EER	2.9686e-04	-0.3579
ENSG00000183604.13,SMG1P5	PRAD	IPA.3	EAG	1.3672e-02	0.2236
chr16:30282487-30284599:-	PRAD	IPA.3	EER	1.3373e-02	0.2243
chr16:30282487-30284599:-	READ	GNF.2	EER	2.2200e-02	0.3855
ENSG00000183604.13,SMG1P5	READ	GNF.2	EAG	2.2200e-02	0.3855
chr16:30282487-30284599:-	SARC	CI.1040	EER	2.9900e-02	0.2414
ENSG00000183604.13,SMG1P5	SARC	CI.1040	EAG	2.9900e-02	0.2414
chr16:30282487-30284599:-	SKCM	JNJ.26854165	EER	4.7840e-02	-0.1630
ENSG00000183604.13,SMG1P5	SKCM	JNJ.26854165	EAG	4.7840e-02	-0.1630
ENSG00000183604.13,SMG1P5	STAD	CCT018159	EAG	1.8355e-02	-0.1634
chr16:30282487-30284599:-	STAD	KU.55933	EER	9.6790e-03	-0.1794
ENSG00000183604.13,SMG1P5	TGCT	EHT.1864	EAG	4.1647e-02	-0.2639
chr16:30282487-30284599:-	TGCT	EHT.1864	EER	4.1647e-02	-0.2639
chr16:30282487-30284599:-	THCA	BX.795	EER	7.5212e-03	0.1810
ENSG00000183604.13,SMG1P5	THCA	BX.795	EAG	7.5212e-03	0.1810
ENSG00000183604.13,SMG1P5	THYM	BIRB.0796	EAG	1.9584e-02	0.2825
chr16:30282487-30284599:-	THYM	BIRB.0796	EER	1.9584e-02	0.2825
chr16:30282487-30284599:-	UCEC	JNK.Inhibitor.VIII	EER	3.1561e-03	-0.2882
ENSG00000183604.13,SMG1P5	UCEC	JNK.Inhibitor.VIII	EAG	8.0181e-03	-0.2587
ENSG00000183604.13,SMG1P5	UCS	Midostaurin	EAG	2.4899e-02	-0.4022
ENSG00000183604.13,SMG1P5	UVM	AZ628	EAG	1.3444e-02	-0.5426

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType